Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy

Science

Volumn 289, Issue 5476, 2000, Pages 119-123

  Geller, David S ^a   Farhi, Anita ^a   Pinkerton, Nikki ^a   Fradley, Michael ^a   Moritz, Michael ^b   Spitzer, Adrian ^b   Meinke, Gretchen ^a   Tsai, Francis T F ^a   Sigler, Paul B ^a   Lifton, Richard P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID RECEPTOR;

ARTICLE; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPERTENSION; MATERNAL HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSCRIPTION REGULATION;

ADOLESCENT; ALDOSTERONE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BINDING, COMPETITIVE; DIMERIZATION; FEMALE; HETEROZYGOTE; HUMANS; HYPERTENSION; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEDIGREE; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGESTERONE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, MINERALOCORTICOID; RECEPTORS, STEROID; STEROIDS;

EID: 0034617130     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.289.5476.119     Document Type: Article

References (25)

1. P. August and M. D. Lindheimer, in Hypertension: Pathophysiology, Diagnosis, and Management, J. H. Laragh and B. M. Brenner, Eds. (Raven, New York, 1995), pp. 2407-2426.
2. R. P. Lifton, Science 272, 676 (1996).
3. D. S. Geller et al., Nature Genet. 19, 279 (1998).
4. Seventy-five index cases with early onset of severe hypertension, many with suppressed renin and/or aldosterone levels, were screened for mutation by single-stranded conformational polymorphism (SSCP) analysis of all coding regions of MR (3). Identified variants were subjected to DNA sequence analysis (3). All clinical studies were approved by the Yale Human Investigation Committee.
5. Sequence alignment was performed with the Megalign Clustal method software (DNAStar).
6. A. Sinaiko, in (1), pp. 209-225.
7. Lod scores were calculated with the LINKAGE program (20), specifying early onset of severe hypertension as an autosomal dominant trait with complete penetrance, a phenocopy rate of 0.001, and a mutant allele frequency of 0.0001.
8. L810 were indistinguishable, and multiple independent preparations of both plasmids yielded indistinguishable results in heterodimer experiments.
9. R. Rupprecht et al., Eur. J. Pharmacol. 247, 145 (1993).
10. D. Moras and H. Gronemeyer, Curr. Opin. Cell Biol. 10, 384 (1998).
11. J. F. Dunn, B. C. Nisula, D. Rodbard, J. Clin. Endocrinol. Metab. 53, 58 (1981).
12. Additional data are available at www.sciencemag. org/feature/data/1051091.shl.
13. S. P. Williams and P. B. Sigler, Nature 393, 392 (1998).
14. J. Fagart et al., EMBO J. 17, 3317 (1998).
15. L810 models were generated from the PR crystal structure (13) with the Turbo Frodo molecular graphics program (http://afmb.cnrs-mrs.fr/ TURBO_FRODO). Residues abutting the ligand were altered to match the MR sequence (G773A, M810S, Y941F, and M960L). In addition, the E774G substitution was incorporated to reflect the rotational freedom C774 confers on helix 3 in MR. The geometry was regularized with Turbo Frodo. Coordinates for aldosterone (23) were superimposed upon progesterone. Parameters for aldosterone were generated with HIC-Up (24). The 21-hydroxyl group was rotated to form a favorable interaction with the N770 side chain (14).
16. 3H]aldosterone and competitor steroid at 0°C in a total volume of 200 μl, and then incubated with 100 μl of a 50% slurry of hydroxyapatite in binding buffer. Samples were centrifuged, washed twice in binding buffer, and then resuspended in ethanol and prepared for scintillation counting. The value for 100% binding was determined by subtracting the number of counts per minute bound in the presence of 500-fold excess of unlabeled aldosterone from the counts bound in the absence of competitor. Nonspecific binding was determined with a 500-fold excess of unlabeled aldosterone. No specific binding was seen in mock-transfected cells.
17. A. M. Brzozowski et al., Nature 389, 753 (1997).
18. W. Bourguet et al., Mol. Cell 5, 289 (2000).
19. J. Arriza et al., Science 237, 258 (1987).
20. G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Proc. Natl. Acad. Sci. U.S.A. 81, 3443 (1984).
21. R. Rupprecht et al., Mol. Endocrinol. 7, 597 (1993).
22. P. Igarashi, D. A. Whyte, K. Li, G. T. Nagami, J. Biol. Chem. 19, 271 (1996).
23. W. L. Duax and H. Haupt, J. Am. Chem. Soc. 94, 5467 (1972).
24. C. J. Kleywegt and T. A. Jones, Acta Crystallogr. D54, 1119 (1998).
25. NX and pMTV-Luc; and P. Igarashi for providing pSV2. Supported in part by an NIH Specialized Center of Research grant in hypertension. R.P.L. is an investigator of the Howard Hughes Medical Institute. Dedicated to the memory of Paul Sigler, whose passion for science remains a source of inspiration.